Legend Biotech Corporation (LEGN)
LEGN Stock Price Chart
Explore Legend Biotech Corporation interactive price chart. Choose custom timeframes to analyze LEGN price movements and trends.
LEGN Company Profile
Discover essential business fundamentals and corporate details for Legend Biotech Corporation (LEGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Jun 2020
Employees
2.90k
Website
https://www.legendbiotech.comCEO
Ying Huang
Description
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
LEGN Financial Timeline
Browse a chronological timeline of Legend Biotech Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is $0.12, while revenue estimate is $355.40m.
Earnings released on 12 May 2026
EPS came in at -$0.15 falling short of the estimated -$0.02 by -650.00%, while revenue for the quarter reached $305.10m , missing expectations by -0.46%.
Earnings released on 10 Mar 2026
EPS came in at -$0.08 surpassing the estimated -$0.17 by +52.94%, while revenue for the quarter reached $306.30m , missing expectations by -0.47%.
Earnings released on 12 Nov 2025
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $272.33m , missing expectations by -0.76%.
Earnings released on 11 Aug 2025
EPS came in at -$0.34 falling short of the estimated -$0.11 by -199.67%, while revenue for the quarter reached $255.06m , beating expectations by +11.40%.
Earnings released on 13 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.23 by +68.99%, while revenue for the quarter reached $195.05m , beating expectations by +0.73%.
Earnings released on 11 Mar 2025
EPS came in at -$0.15 surpassing the estimated -$0.25 by +39.52%, while revenue for the quarter reached $186.52m , beating expectations by +4.27%.
Earnings released on 12 Nov 2024
EPS came in at -$0.34 surpassing the estimated -$0.35 by +3.52%, while revenue for the quarter reached $160.21m , beating expectations by +11.32%.
Earnings released on 9 Aug 2024
EPS came in at -$0.05 surpassing the estimated -$0.54 by +90.74%, while revenue for the quarter reached $186.52m , beating expectations by +48.92%.
Earnings released on 13 May 2024
EPS came in at -$0.16 surpassing the estimated -$0.29 by +44.83%, while revenue for the quarter reached $93.99m , missing expectations by -34.38%.
Earnings released on 11 Mar 2024
EPS came in at -$0.40 surpassing the estimated -$0.70 by +42.86%, while revenue for the quarter reached $79.46m , missing expectations by -15.53%.
Earnings released on 20 Nov 2023
EPS came in at -$0.17 surpassing the estimated -$0.56 by +69.64%, while revenue for the quarter reached $96.01m , missing expectations by -1.28%.
Earnings released on 15 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$0.69 by +60.87%, while revenue for the quarter reached $73.33m , beating expectations by +29.48%.
Earnings released on 18 May 2023
EPS came in at -$0.40 surpassing the estimated -$0.56 by +28.57%, while revenue for the quarter reached $36.34m , missing expectations by -13.85%.
Earnings released on 17 Feb 2023
EPS came in at -$0.41 surpassing the estimated -$0.44 by +6.82%, while revenue for the quarter reached $27.52m , missing expectations by -23.69%.
Earnings released on 1 Jun 2022
EPS came in at -$0.24 surpassing the estimated -$0.37 by +35.14%, while revenue for the quarter reached $40.83m , beating expectations by +63.31%.
Earnings released on 18 Mar 2022
EPS came in at -$0.30 surpassing the estimated -$0.35 by +14.29%, while revenue for the quarter reached $39.00m , beating expectations by +173.25%.
Earnings released on 16 Nov 2021
EPS came in at -$0.43 falling short of the estimated -$0.35 by -22.86%, while revenue for the quarter reached $16.88m , beating expectations by +115.51%.
Earnings released on 23 Aug 2021
EPS came in at -$0.32 falling short of the estimated -$0.31 by -3.23%, while revenue for the quarter reached $20.83m , beating expectations by +166.08%.
LEGN Stock Performance
Access detailed LEGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
